Total Payments
$14,084
2024 Payments
$657.15
Companies
37
Transactions
497
Medicare Patients
10,731
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$10,949 (77.7%)
Consulting$2,440 (17.3%)
Other$600.00 (4.3%)
Education$94.60 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,949 | 481 | 77.7% |
| Consulting Fee | $2,440 | 3 | 17.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $600.00 | 1 | 4.3% |
| Education | $94.60 | 12 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $3,022 | 57 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,628 | 76 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,297 | 48 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,280 | 58 | $0 (2024) |
| Amgen Inc. | $1,028 | 38 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $934.76 | 30 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $841.23 | 11 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $798.46 | 39 | $0 (2024) |
| Lilly USA, LLC | $675.71 | 31 | $0 (2024) |
| PFIZER INC. | $383.03 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $657.15 | 28 | Lilly USA, LLC ($217.68) |
| 2023 | $958.03 | 35 | Amgen Inc. ($170.62) |
| 2022 | $1,975 | 71 | AstraZeneca Pharmaceuticals LP ($362.11) |
| 2021 | $4,200 | 75 | Novo Nordisk Inc ($2,180) |
| 2020 | $640.69 | 33 | Novo Nordisk Inc ($185.25) |
| 2019 | $1,760 | 81 | Boehringer Ingelheim Pharmaceuticals, Inc. ($450.28) |
| 2018 | $1,651 | 86 | E.R. Squibb & Sons, L.L.C. ($289.13) |
| 2017 | $2,243 | 88 | E.R. Squibb & Sons, L.L.C. ($548.26) |
All Payment Transactions
497 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Diabetes | ||||||
| 12/11/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $13.25 | General |
| Category: Coronary | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $28.31 | General |
| Category: Cardiovascular | ||||||
| 10/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: Cardio-renal | ||||||
| 10/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Education | In-kind items and services | $19.62 | General |
| Category: Cardio-renal | ||||||
| 09/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: DIABETES | ||||||
| 09/16/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Endocrinology | ||||||
| 08/22/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Endocrinology | ||||||
| 08/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: DIABETES | ||||||
| 08/12/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $10.78 | General |
| Category: Heart Failure and Hypertension | ||||||
| 08/07/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $23.01 | General |
| Category: Coronary | ||||||
| 08/01/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $30.03 | General |
| Category: Medical Device | ||||||
| 07/10/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Diabetes | ||||||
| 06/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.38 | General |
| Category: DIABETES | ||||||
| 05/22/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $24.94 | General |
| Category: Cardiovascular | ||||||
| 05/13/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Diabetes | ||||||
| 05/13/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: Diabetes | ||||||
| 05/09/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Diabetes | ||||||
| 05/09/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 05/02/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $26.19 | General |
| Category: Diabetes | ||||||
| 04/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: DIABETES | ||||||
| 03/27/2024 | Intra-Sana Laboratories | RELTONE 200 MG (Drug), GLYCATE, RELTONE 400 MG | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: GALLSTONES | ||||||
| 03/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/17/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 3,186 | 5,178 | $2.3M | $323,008 |
| 2022 | 25 | 2,628 | 4,105 | $1.9M | $265,314 |
| 2021 | 27 | 2,593 | 3,826 | $1.9M | $275,050 |
| 2020 | 24 | 2,324 | 3,175 | $1.5M | $205,863 |
Total Patients
10,731
Total Services
16,284
Medicare Billing
$1.1M
Procedure Codes
104
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 498 | 1,404 | $772,200 | $152,150 | 19.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 246 | 250 | $466,134 | $40,876 | 8.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 166 | 166 | $106,572 | $25,287 | 23.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 108 | 148 | $55,500 | $12,196 | 22.0% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 62 | 62 | $108,872 | $11,327 | 10.4% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 67 | 69 | $58,305 | $10,905 | 18.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 496 | 827 | $119,915 | $10,427 | 8.7% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 114 | 114 | $20,064 | $8,128 | 40.5% |
| 93040 | Electrocardiogram (ecg) 1 to 3 leads with review by physician | Office | 2023 | 420 | 631 | $238,518 | $7,326 | 3.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $48,853 | $5,990 | 12.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 347 | 706 | $14,650 | $5,923 | 40.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 136 | 139 | $15,012 | $4,878 | 32.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 32 | $23,840 | $4,868 | 20.4% |
| 99350 | Residence visit for established patient with high level of medical decision making, per day, if using time, at least 60 minutes | Office | 2023 | 15 | 25 | $22,625 | $4,027 | 17.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 55 | 55 | $33,715 | $3,595 | 10.7% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 58 | 70 | $53,410 | $3,026 | 5.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $13,845 | $2,490 | 18.0% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 15 | 16 | $7,440 | $1,586 | 21.3% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 27 | 39 | $10,725 | $1,551 | 14.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 29 | 90 | $24,750 | $1,180 | 4.8% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 66 | 66 | $7,920 | $1,166 | 14.7% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 16 | 21 | $11,844 | $1,125 | 9.5% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 66 | 66 | $5,214 | $776.24 | 14.9% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 17 | 17 | $1,275 | $569.33 | 44.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 11 | 11 | $7,700 | $568.25 | 7.4% |
About Dr. David Khaski, MD
Dr. David Khaski, MD is a Cardiovascular Disease healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/13/2007. The National Provider Identifier (NPI) number assigned to this provider is 1720268220.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Khaski, MD has received a total of $14,084 in payments from pharmaceutical and medical device companies, with $657.15 received in 2024. These payments were reported across 497 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($10,949).
As a Medicare-enrolled provider, Khaski has provided services to 10,731 Medicare beneficiaries, totaling 16,284 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Internal Medicine
- Location Brooklyn, NY
- Active Since 11/13/2007
- Last Updated 04/05/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1720268220
Products in Payments
- Ozempic (Drug) $2,743
- XARELTO (Drug) $1,628
- ELIQUIS (Drug) $1,382
- JARDIANCE (Drug) $1,006
- FARXIGA (Drug) $988.40
- Repatha (Biological) $936.25
- MULTAQ (Drug) $809.13
- ENTRESTO (Drug) $714.27
- TRULICITY (Drug) $200.94
- BRILINTA (Drug) $196.81
- WATCHMAN (Device) $178.53
- MOUNJARO (Drug) $168.19
- Victoza (Drug) $155.42
- PRALUENT ALIROCUMAB INJECTION (Biological) $144.42
- LifeVest (Device) $121.84
- Ranexa (Drug) $119.26
- VERQUVO (Drug) $112.69
- Rybelsus (Drug) $112.36
- CAMZYOS (Drug) $108.77
- Vascepa (Drug) $102.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Brooklyn
Dr. Felix Yang, M.d, M.D
Cardiovascular Disease — Payments: $599,451
Cardiovascular Disease $599,451
Ozgen Dogan, Md, MD
Cardiovascular Disease — Payments: $367,116
Cardiovascular Disease $367,116
Dr. Adam Budzikowski, M.d., Ph.d, M.D., PH.D
Cardiovascular Disease — Payments: $346,063
Cardiovascular Disease $346,063
Dr. Peter Rouvelas, M.d, M.D
Cardiovascular Disease — Payments: $339,378
Cardiovascular Disease $339,378
Dr. Ronald Wharton, M.d, M.D
Cardiovascular Disease — Payments: $298,083
Cardiovascular Disease $298,083
Dr. Sorin Brener, Md, MD
Cardiovascular Disease — Payments: $225,799
Cardiovascular Disease $225,799